Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

THE GROUP'S GLOBAL INNOVATIVE NEBULIZED INHALATION AGENT GPN01564 FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS HAS BEEN APPROVED TO CONDUCT PHASE I CLINICAL TRIAL

This announcement is made by the board of directors (the "**Board**") of Grand Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board is pleased to announce that GPN01564, a global innovative nebulized inhalation agent independently developed by the Group for the treatment of Respiratory Syncytial Virus ("**RSV**"), has been approved by the National Medical Products Administration of the People's Republic of China (NMPA) to conduct Phase I clinical trial. This marks another significant milestone for the Group in the direction of anti-infection in the field of respiratory and critical and severe disease.

GPN01564 is an inhibitor of the RSV fusion protein ("**F protein**"). As a Type I membrane fusion protein, the F protein has emerged as one of the most promising targets for RSV prevention and treatment, as it combines the unique antigenic epitope conformation of the pre-fusion state and high capacity to induce neutralizing antibodies. Meanwhile, the product is designed for administration via nebulized inhalation. By targeting the lungs directly rather than requiring systemic delivery, it enables precise, non-invasive administration. This approach enhances the patient experience and offers a distinct clinical advantage in terms of medication compliance. Preclinical study results indicate that GPN01564 possesses favorable druggability, safety, and efficacy.

RSV is a major pathogen responsible for lower respiratory tract infections. While individuals of any age can contract RSV, the disease tends to be more severe in infants, particularly premature infants and children with chronic lung disease or congenital heart disease (CHD), as well as in the elderly. Statistics indicate that in 2019, there were 33 million cases of acute lower respiratory tract infections ("**ALRTIs**") caused by RSV globally. Each year, RSV leads to over 3.6 million hospitalizations among children under the age of five, resulting in approximately

100,000 deaths. China has one of the highest burdens of RSV infection worldwide. In 2019, there were approximately 3.5 million cases of RSV-associated ALRTIs in children under five in China, accounting for over 10% of the global total, and with 620,000 to 950,000 hospitalizations, representing 17% to 24% of the global figure and ranking second highest in the world. Currently, the only available preventive measures against RSV infection for infants, young children, and the elderly are monoclonal antibodies and vaccines. According to the *Expert consensus on the collaboration of medical and preventive care for the prevention and treatment of respiratory syncytial virus infection*, currently there are no specific antiviral drugs for RSV; therefore, clinical management primarily focuses on symptomatic and supportive care, such as oxygen therapy and fluid replacement, tailored to the individual patient's condition. Consequently, it is evident that clinical needs in the treatment of RSV infection remain largely unmet.

GPN01564 is a key product reserve within the Group's anti-infective innovation platform in the respiratory and critical and severe disease segment. It complements the segment's commercialized innovative portfolio, creating a synergistic product portfolio that establishes a closed-loop management system covering the entire airway and the full disease cycle. Specifically, the innovative compound nasal spray Ryaltris® addresses upper airway inflammation, such as allergic rhinitis; the innovative inhaled therapies Enerzair® Breezhaler® and Atectura® Breezhaler® focus on the long-term control of lower airway chronic diseases like asthma; and GPN01564 fills the gap in RSV-specific antiviral treatment. Together, they drive the platform's evolution from a cluster of products for chronic airway diseases into a systemic respiratory treatment ecosystem. The respiratory and critical and severe disease segment is one of the core strategic segments of the Group, with a commercial portfolio covering indications such as rhinitis, bronchitis, pneumonia, asthma, and chronic obstructive pulmonary disease. Among them, the core product Qienuo® is an exclusive product in China and is recommended by numerous clinical guidelines and expert consensus statements. Regarding payment, Ryaltris® was included for the first time in the *National Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance Drug Catalog (2026)** (《國家基本醫療保險、生育保險和工傷保險藥品目錄(2026年)》, the "**National Reimbursement Drug Catalog**") this year, while Enerzair® Breezhaler® and Atectura® Breezhaler® successfully renewed their inclusion in the National Reimbursement Drug Catalog, which will enhance patient access to these medications and accelerate market penetration.

GPN01564 is a global innovative drug independently developed by the Group, leveraging its proprietary innovative anti-infection platform. Centered on the Wuhan Optics Valley International R&D Center, this platform forms a global R&D network for innovative anti-infective drugs, spanning the whole chain from "early-stage discovery, process development, and clinical translation". The R&D Center spans over 13,000 square meters and is equipped with state-of-the-art scientific instrumentation. It supports the R&D of small-molecule drugs, peptides, and complex, high-end pharmaceutical formulations. Specialized laboratories have been established for pharmacodynamic evaluation, process thermal safety assessment, crystallization science, and continuous-flow manufacturing. The platform holds the designation of a National-level Enterprise Technology Center* (國家級企業技術中心) and qualification for provincial-level (or higher) R&D innovation platforms, as well as a national-level postdoctoral research workstation. Driven by the mission to "overcome major infectious diseases", the platform targets high-burden areas, such as RSV, sepsis, acute respiratory distress syndrome (ARDS), influenza, herpes viruses, COVID-19, and Gram-negative bacterial infections, thereby directly addressing significant unmet clinical needs. A continuous pipeline of projects has been established, covering candidate molecule discovery, preclinical research,

regulatory filings, and clinical development, which have been advanced in an orderly manner. Moving forward, the Group will continue to strengthen its strategic investment in this platform, focusing on enhancing source innovation, molecular discovery efficiency, and clinical translation capabilities. This will accelerate the platform's evolution into a comprehensive therapeutic system, driving the long-term, high-quality development of anti-infective solutions within the respiratory and critical and severe disease segment.

The Group always puts focus on the R&D of innovative products and advanced technologies. Adhering to a patient-centered and innovation-driven approach, the Group will continue to increase its investment in world-class innovative products and advanced technologies to meet unmet clinical needs and enrich its product pipeline and improve supply chain. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities, to accelerate the commercialization process for innovative products and provide patients with more advanced and diverse treatment options globally.

Warning:

The aforementioned product is still in the R&D stage. The approval of commercialization, manufacturing and sale of such product is subject to various factors with uncertainty, and whether it can ultimately benefit is still uncertain. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

Note: The English transliteration of the Chinese name(s) in this announcement is included for information purpose only, and should not be regarded as the official English name(s) of such Chinese name(s).

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 19 November 2026

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Mr. Yang Guang and Ms. Lam Chit Yee Jessica, and four independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*